174 related articles for article (PubMed ID: 36624289)
41. The impact of antinuclear antibodies seroconversion induced by anti-tumor necrosis factor α agents on the clinical outcomes in rheumatic patients.
Martins A; Oliveira D; Martins FR; Rato MS; Pinheiro FO; Fonseca D; Garcia S; Fernandes BM; Pimenta S; Vaz C; Costa L; Bernardes M
ARP Rheumatol; 2023 Apr; ():. PubMed ID: 37178156
[TBL] [Abstract][Full Text] [Related]
42. Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study.
Cheleschi S; Tenti S; Bedogni G; Fioravanti A
Transl Res; 2022 Jan; 239():18-34. PubMed ID: 34380068
[TBL] [Abstract][Full Text] [Related]
43. Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study.
Stouten V; Pazmino S; Verschueren P; Mamouris P; Westhovens R; de Vlam K; Bertrand D; Van der Elst K; Vaes B; De Cock D
RMD Open; 2021 Jun; 7(2):. PubMed ID: 34158353
[TBL] [Abstract][Full Text] [Related]
44. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
45. Doppler enthesitis: a potential useful outcome in the assessment of axial spondyloarthritis and psoriatic arthritis.
Molina Collada J; Macía-Villa C; Plasencia C; Álvaro-Gracia JM; de Miguel E
Clin Rheumatol; 2021 May; 40(5):2013-2020. PubMed ID: 33034818
[TBL] [Abstract][Full Text] [Related]
46. Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study.
Leung YY; Eder L; Orbai AM; Coates LC; de Wit M; Smolen JS; Kiltz U; Palominos P; Canete JD; Scrivo R; Balanescu A; Dernis E; Meisalu S; Soubrier M; Kalyoncu U; Gossec L
RMD Open; 2023 Sep; 9(3):. PubMed ID: 37709527
[TBL] [Abstract][Full Text] [Related]
47. Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire.
Gossec L; Chauvin P; Saraux A; Hudry C; Cukierman G; de Chalus T; Dreuillet C; Saulot V; Tong S; Russo-Marie F; Joubert JM; Berenbaum F
Ann Rheum Dis; 2018 Feb; 77(2):258-263. PubMed ID: 29102955
[TBL] [Abstract][Full Text] [Related]
48. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
Michelsen B; Ørnbjerg LM; Kvien TK; Pavelka K; Nissen MJ; Nordström D; Santos MJ; Koca SS; Askling J; Rotar Z; Gudbjornsson B; Codreanu C; Loft AG; Kristianslund EK; Mann HF; Ciurea A; Eklund KK; Vieira-Sousa E; Yazici A; Jacobsson L; Tomšič M; Löve TJ; Ionescu R; van der Horst-Bruinsma IE; Iannone F; Pombo-Suarez M; Jones GT; Hyldstrup LH; Krogh NS; Hetland ML; Østergaard M
Rheumatology (Oxford); 2020 Sep; 59(9):2455-2461. PubMed ID: 31960053
[TBL] [Abstract][Full Text] [Related]
49. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study.
Kerola AM; Kazemi A; Rollefstad S; Lillegraven S; Sexton J; Wibetoe G; Haavardsholm EA; Kvien TK; Semb AG
Rheumatology (Oxford); 2022 Nov; 61(12):4656-4666. PubMed ID: 35377442
[TBL] [Abstract][Full Text] [Related]
50. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis.
Hagège B; Tan E; Gayraud M; Fautrel B; Gossec L; Mitrovic S
Rheumatology (Oxford); 2020 Aug; 59(8):1818-1825. PubMed ID: 32118267
[TBL] [Abstract][Full Text] [Related]
51. Sociodemographic and clinical variables associated with negative illness perception in patients newly diagnosed with rheumatoid arthritis, axial spondyloarthritis, or psoriatic arthritis-a survey based cross-sectional study.
Lindgren LH; de Thurah A; Thomsen T; Hetland ML; Aadahl M; Vestergaard SB; Kristensen SD; Esbensen BA
Rheumatol Int; 2024 Jun; 44(6):1119-1131. PubMed ID: 38563971
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G
Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736
[TBL] [Abstract][Full Text] [Related]
53. The role of pain catastrophizing in pain perception among patients with rheumatoid arthritis without clinical signs of inflammation.
Abe T; Tamura M; Azuma N; Matsui K
Musculoskeletal Care; 2023 Sep; 21(3):694-701. PubMed ID: 36748978
[TBL] [Abstract][Full Text] [Related]
54. Pain catastrophizing hinders Disease Activity Score 28 - erythrocyte sedimentation rate remission of rheumatoid arthritis in patients with normal C-reactive protein levels.
Yoshida T; Hashimoto M; Horiguchi G; Murakami K; Murata K; Nishitani K; Watanabe R; Yamamoto W; Tanaka M; Morinobu A; Ito H; Matsuda S; Uehara R
Int J Rheum Dis; 2021 Dec; 24(12):1520-1529. PubMed ID: 34698449
[TBL] [Abstract][Full Text] [Related]
55. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study.
Michelsen B; Kristianslund EK; Sexton J; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
Ann Rheum Dis; 2017 Nov; 76(11):1906-1910. PubMed ID: 28733473
[TBL] [Abstract][Full Text] [Related]
56. Increase in axial spondyloarthritis diagnoses after the introduction of the ASAS criteria: a systematic review.
Jamal M; van Delft ETAM; den Braanker H; Kuijper TM; Hazes JMW; Lopes Barreto D; Weel AEAM
Rheumatol Int; 2023 Apr; 43(4):639-649. PubMed ID: 36637486
[TBL] [Abstract][Full Text] [Related]
57. Fatigue in psoriatic arthritis: Is it related to disease activity?
Lai TL; Au CK; Chung HY; Leung MC; Ng WL; Lau CS
Int J Rheum Dis; 2021 Mar; 24(3):418-425. PubMed ID: 33506651
[TBL] [Abstract][Full Text] [Related]
58. Patients with rheumatic diseases share similar patterns of healthcare resource utilization.
Mars NJ; Kerola AM; Kauppi MJ; Pirinen M; Elonheimo O; Sokka-Isler T
Scand J Rheumatol; 2019 Jul; 48(4):300-307. PubMed ID: 30836033
[No Abstract] [Full Text] [Related]
59. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
[TBL] [Abstract][Full Text] [Related]
60. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
Michelsen B; Sexton J; Wierød A; Bakland G; Rødevand E; Krøll F; Kvien TK
Semin Arthritis Rheum; 2020 Feb; 50(1):12-16. PubMed ID: 31358361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
